Summary
BeOne Medicines Ltd. (ONC) filed an 8-K on January 31, 2023, announcing an amendment to its Share Purchase Agreement with Amgen Inc. This amendment, effective January 30, 2023, involves Amgen relinquishing its right to appoint a director to BeOne's board of directors. This change reflects BeOne's global growth and is not expected to impact the company's strategic direction or operations. While Amgen is no longer appointing a director, the current designee, Anthony C. Hooper, who was Amgen's appointed director, will continue to serve on BeOne's board. Mr. Hooper was re-elected by shareholders in 2022 for a term ending in 2025, indicating continued confidence from the broader shareholder base. This development is primarily a governance adjustment resulting from the evolution of the relationship between the two companies.
Key Highlights
- 1Amgen has relinquished its right to appoint a director to BeOne Medicines' board of directors.
- 2The change is effective as of January 30, 2023, via Amendment No. 3 to the Share Purchase Agreement.
- 3BeOne Medicines cites its global growth as the reason for Amgen's decision.
- 4The current director designee, Anthony C. Hooper, will remain on the board.
- 5Mr. Hooper's current term as a director ends in 2025, having been re-elected by shareholders in 2022.
- 6The original Share Purchase Agreement involved Amgen investing approximately $2.78 billion for ordinary shares (ADSs) in BeOne Medicines.